• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
Home AI Roundup

Artificial intelligence matches dermatologists in melanoma diagnosis

byDeepti Shroff
September 15, 2025
in AI Roundup, Dermatology, Oncology
Reading Time: 2 mins read
Patient Basics: Melanoma
Share on FacebookShare on Twitter

1. Artificial intelligence triage for melanoma shows more than 90 percent sensitivity and is now in trials within the National Health Service.

2. Referrals for suspected skin cancer in England have doubled in the past decade, making early triage critical.

England’s health service began piloting an artificial intelligence tool called Deep Ensemble for Recognition of Malignancy, abbreviated as DERM, across several hospitals as part of a three-year evaluation, reported on August 27 in Nature. The system analyzes skin lesion images and prioritizes which patients should be seen first, offering sensitivity for melanoma that exceeded 90 percent in early studies. This level of accuracy compares favorably with most board-certified dermatologists, who average closer to 82 to 85 percent sensitivity in large audits. Importantly, DERM is being tested on patients with a range of skin tones and lesion types, addressing concerns that earlier models did not perform equally across populations. Referrals for suspected melanoma in the National Health Service have increased from roughly 450,000 in 2013 to more than 1 million in 2023, straining capacity. In some regions, patients wait over three months for initial dermatology review, a gap that may worsen outcomes if dangerous lesions are missed. Artificial intelligence may help by consistently triaging which lesions require dermoscopy and biopsy most urgently. Clinicians emphasize that the system does not replace dermatologists but instead serves as a screening layer. Safety monitoring will track false negatives closely to ensure early cancers are not overlooked. If results hold, NHS leaders say the program could shorten waiting times by weeks. For physicians, the promise is a more efficient pathway to identify high-risk lesions. By embedding artificial intelligence into referral systems, national health services may finally balance growing demand with limited specialist supply.

Image: PD

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

2MM: AI Roundup: NHS England expands Microsoft Copilot nationwide, ARPA-H advances autonomous cardiovascular AI, FDA advisors back Moderna’s mRNA influenza vaccine, and UpDoc earns first clearance for a patient-facing large language model

Perioperative vitamin C supplementation may not reduce bleeding in percutaneous renal biopsy patients

Food and Drug Administration reviews model for predicting drug related liver injury

Tags: artificial intelligencebiopsydermatologymelanomaskin cancer
Previous Post

2 Minute Medicine Rewind September 15, 2025

Next Post

Sarcopenia at diagnosis is associated with greater risk of relapse in children with Crohn’s disease

RelatedReports

2MM: AI Roundup- AI Cancer Test, Smarter Hospitals, Faster Drug Discovery, and Mental Health Tech [May 2nd, 2025]
AI Roundup

2MM: AI Roundup: NHS England expands Microsoft Copilot nationwide, ARPA-H advances autonomous cardiovascular AI, FDA advisors back Moderna’s mRNA influenza vaccine, and UpDoc earns first clearance for a patient-facing large language model

September 3, 2026
Blood type correlates with egg reserve in infertile women
Nephrology

Perioperative vitamin C supplementation may not reduce bleeding in percutaneous renal biopsy patients

July 10, 2026
American College of Physicians releases principles to guide patient partnership in health care
All Specialties

Food and Drug Administration reviews model for predicting drug related liver injury

September 4, 2026
2MM: AI Roundup- AI Cancer Test, Smarter Hospitals, Faster Drug Discovery, and Mental Health Tech [May 2nd, 2025]
AI Roundup

2MM: AI Roundup: Food and Drug Administration reviews liver injury prediction tool, Joint Commission launches healthcare artificial intelligence certification, governance playbooks aim to standardize adoption, and pediatric hospitals bring generative tools to the frontline

June 15, 2026
Next Post
Biosimilar to infliximab shows equivalent safety and efficacy for treating Crohn’s disease

Sarcopenia at diagnosis is associated with greater risk of relapse in children with Crohn's disease

Increased number of daily steps linked with decreased mortality in older women

Semaglutide and tirzepatide may be cost-effective for knee osteoarthritis in patients with obesity

Survival greater in cervical cancer patients undergoing abdominal hysterectomy compared to minimally invasive techniques: the LACC trial

Laparoscopic sacrocolpopexy, transvaginal mesh and lateral suspension are effective at improving quality of life in patients with advanced apical prolapse

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Daraxonrasib showed antitumor activity in previously treated RAS-mutant non–small-cell lung cancer
  • The mortality in-hospital for patients undergoing elective catheter ablation for atrial fibrillation is low
  • Azacitidine–venetoclax improved event-free survival in induction-eligible AML
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.

2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in